Research Overview

The ultimate goal of the Look group's studies is to reveal mutant genes, thus providing candidate targets for the development of new therapies. To this end it is exploring:

  • Models of leukemogenesis,particularly the antiapoptotic transcriptional pathway downstream of E2A-HLF, a chimeric oncoprotein activated by chromosomal translocation in childhood leukemia.
  • Developmental pathways subverted in human leukemias and solid tumors. They are conducting a genome-wide mutagenesis screen in zebrafish to identify genes required for normal myeloid cell development in the hematopoietic system.
  • Pathways that lead to T-cell leukemia. They have shown that human T-cell leukemias can be divided into five major subtypes based on the expression of oncogenes that initiate malignant transformation in thymocytes and have overexpressed these oncogenes in zebrafish T-cell progenitors.

About Thomas Look

Thomas Look received his MD and completed an internship and residency in pediatrics at the University of Michigan. He subsequently completed his fellowship in pediatric oncology at St. Jude Childrens Research Hospital in Memphis.He was named Second Annual Lecturer in Leukemia at The Hospital for Sick Children, Toronto, Canada, 2000; Second Annual Giulio J. D'Angio Lecturer, University of Pennsylvania Cancer Center, 1999; and received an Award for Excellence in Pediatric Research, American Academy of Pediatrics, 1995.

Researcher Services

Researcher Areas

  • Leukemogenesis

Research Departments

Research Divisions

Researcher Centers